TY - JOUR
T1 - Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer
T2 - Results of the west japan thoracic oncology group trial (WJTOG0401)
AU - Kaneda, Hiroyasu
AU - Okamoto, Isamu
AU - Hayashi, Hidetoshi
AU - Yoshioka, Hiroshige
AU - Miyazaki, Masaki
AU - Kudoh, Shinzoh
AU - Kimura, Tatsuo
AU - Sugiura, Takamune
AU - Sawa, Toshiyuki
AU - Takeda, Koji
AU - Iwamoto, Yasuo
AU - Satouchi, Miyako
AU - Akita, Kenji
AU - Saito, Hiroshi
AU - Goto, Isao
AU - Shibata, Kazuhiko
AU - Fukuoka, Masahiro
AU - Nakagawa, Kazuhiko
PY - 2010/1
Y1 - 2010/1
N2 - BACKGROUND: Amrubicin is a synthetic anthracycline drug that is a potent inhibitor of topoisomerase II. We have performed a multicenter phase II trial to evaluate the efficacy and safety of amrubicin for patients with previously treated non-small cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC who experienced disease recurrence after one platinum-based chemotherapy regimen were eligible for enrollment in the study. Amrubicin was administered by intravenous injection at a dose of 40 mg/m2 on 3 consecutive days every 3 weeks. RESULTS: Sixty-one enrolled patients received a total of 192 treatment cycles (median, 2; range, 1-15). Response was as follows: complete response, 0; partial response, seven (11.5%); stable disease, 20 (32.8%); and progressive disease, 34 (55.7%). Median progression-free survival was 1.8 months, whereas median overall survival was 8.5 months, and the 1-year survival rate was 32%. Hematologic toxicities of grade 3 or 4 included neutropenia (82.0%), leukopenia (73.8%), thrombocytopenia (24.6%), and anemia (27.9%). Febrile neutropenia occurred in 18 patients (29.5%). One treatment-related death due to infection was observed. Nonhematologic toxicities were mild. CONCLUSIONS: Amrubicin is a possible alternative for second-line treatment of advanced NSCLC, although a relevant hematological toxicity is significant, especially with a febrile neutropenia.
AB - BACKGROUND: Amrubicin is a synthetic anthracycline drug that is a potent inhibitor of topoisomerase II. We have performed a multicenter phase II trial to evaluate the efficacy and safety of amrubicin for patients with previously treated non-small cell lung cancer (NSCLC). METHODS: Patients with advanced NSCLC who experienced disease recurrence after one platinum-based chemotherapy regimen were eligible for enrollment in the study. Amrubicin was administered by intravenous injection at a dose of 40 mg/m2 on 3 consecutive days every 3 weeks. RESULTS: Sixty-one enrolled patients received a total of 192 treatment cycles (median, 2; range, 1-15). Response was as follows: complete response, 0; partial response, seven (11.5%); stable disease, 20 (32.8%); and progressive disease, 34 (55.7%). Median progression-free survival was 1.8 months, whereas median overall survival was 8.5 months, and the 1-year survival rate was 32%. Hematologic toxicities of grade 3 or 4 included neutropenia (82.0%), leukopenia (73.8%), thrombocytopenia (24.6%), and anemia (27.9%). Febrile neutropenia occurred in 18 patients (29.5%). One treatment-related death due to infection was observed. Nonhematologic toxicities were mild. CONCLUSIONS: Amrubicin is a possible alternative for second-line treatment of advanced NSCLC, although a relevant hematological toxicity is significant, especially with a febrile neutropenia.
UR - http://www.scopus.com/inward/record.url?scp=76149117204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76149117204&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3181c07c6c
DO - 10.1097/JTO.0b013e3181c07c6c
M3 - Article
C2 - 19884859
AN - SCOPUS:76149117204
SN - 1556-0864
VL - 5
SP - 105
EP - 109
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 1
ER -
